Treatment of Cannabis Use Disorder Among Adults with Comorbid Attention-Deficit/Hyperactivity Disorder
Medication treatment of marijuana use and Attention-Deficit/Hyperactivity disorder
Sponsor: National Institute on Drug Abuse
Enrolling: Male and Female Patients
Study Length: 13 Weeks
Clinic Visits: 25
IRB Number: 7280
U.S. Govt. ID: NCT02803229
Contact: Daniel Brooks: 212-923-3031 /
Additional Study Information: The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
This study is closed
Frances Levin, MD
Do You Qualify?
Are you currently using marijuana? Yes No
Do you use marijuana at least 5 days per week? Yes No
Are you between the ages of 18 and 65? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Daniel Brooks